Pacira Pharmaceuticals Statement on FDA Advisory Committee for EXPAREL® for Use as a Nerve Block to Produce Regional Analgesia
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/9/2026
- S&P 500 falls as AI worries hit software makers
- Brent crude hits six-week high near $97 as Houthi strike targets Saudi Aramco
- Qualcomm stock surges 9.5% on Amazon AI deal & 25M share warrant
- Energy stocks rise premarket as oil prices climb on Middle East supply fears
- Novartis shares plunge 10% as failed drug trial clouds growth outlook
- Harry and Meghan surprised by King Charles' letter on their status
- Citi initiates UiPath coverage with Buy rating and $23 target
- S&P 500 falls as AI worries hit software makers
- WestPark Capital Starts Akebia Therapeutics (AKBA) at Buy
- After an 18% summer selloff in chip stocks, Citi asks what comes next
- After-Hours Movers: LULU, IOT, PATH, DOCU, ASAN, GWRE, ZS, PL, SWBI, OXM
- After-Hours Movers: AVGO, SNOW, HPE, NTAP, NTSK, CHPT, FIVE, TLYS, PVH, RARE
- After-Hours Movers: DELL, PANW, GTLB, CRDO, MDB, HPE, SMCI
- After-Hours Movers: WDAY, ADSK, S, RBRK, MRVL, ULTA, GAP, AFRM
- After-Hours Movers: NVDA, CRM, SNPS, CRWD, OKTA, NTNX
Needham & Company Downgrades Pacira Pharmaceuticals (PCRX) to Hold
February 16, 2018 7:20 AM ESTNeedham & Company downgraded Pacira Pharmaceuticals (NASDAQ: PCRX) from Buy to Hold.
Analyst Serge Belanger commented, "The FDA's briefing documents presaged a difficult AdCom panel review for Exparel's potential label expansion to nerve blocks. Over the 2-day panel, panel members echoed the FDA's concerns... More
Pacira Pharmaceuticals (PCRX) PT Lowered to $32 at BMO Capital
February 16, 2018 6:11 AM ESTBMO Capital lowered its price target on Pacira Pharmaceuticals (NASDAQ: PCRX) to $32.00 (from $41.00) while maintaining a Market Perform rating.
Analyst Gary Nachman commented, "FDA panel voted against approving the nerve block (NB) indication for Exparel (6 No, 4 Yes). We anticipated a complicated... More
Pacira Pharma (PCRX) to Resume Trading at 4:15 pm ET
February 15, 2018 3:51 PM ESTPacira Pharma (NASDAQ: PCRX) to Resume Trading at 4:15 pm ET
... MorePacira Pharma (PCRX) Confirms Only Four FDA Committee Members Voted to Recommend Approval of EXPAREL sNDA
February 15, 2018 3:36 PM ESTPacira Pharmaceuticals, Inc. (NASDAQ: PCRX), announced today that the U.S. Food and Drug Administrations (FDA) Anesthetic and Analgesic Drug Products Advisory Committee did not reach a unanimous decision on the efficacy and safety of the use of EXPAREL® (bupivacaine liposome injectable suspension) as a nerve block to produce regional analgesia. The committees feedback will be considered by the FDA in its review of the companys sNDA seeking expansion of the... More
